Mode
Text Size
Log in / Sign up
Phase 2 N=103 Randomized Quadruple-blind Treatment

Mifepristone Treatment of Alcohol Use Disorder

Alcohol Dependence · Alcohol Use Disorders · Alcohol Abuse · Alcoholism

Enrolled (actual)
103
Serious AEs
1.0%
Results posted
Oct 2022
Primary outcome: Primary: Drinking Quantity Per Day — 1.25; 1.38; 1.10 Standard drinks per day — p=0.51

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Mifepristone 1200 mg daily (Drug); Standardized behavioral therapy (Behavioral); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
The Scripps Research Institute
Primary completion
Nov 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Drinking Quantity Per Day
1.25; 1.38; 1.10 0.51
SECONDARY
Craving
29.02; 33.66; 28.33 0.50

Summary

This is an 8-week, randomized, double-blind, placebo-controlled, 2 arm, parallel groups, study of 1-week of treatment with mifepristone (0, 1200 mg/d) given in conjunction with 8 weeks of manual-guided counseling, and a follow-up visit at Week 12.

Eligibility Criteria

Inclusion Criteria

  • Male or female volunteers, 18-65 years of age
  • Meets Diagnostic and Statistical Manual (DSM)-V criteria for current alcohol use disorder of moderate or greater severity, defined by DSM-V as ≥ 4 symptoms
  • Abstinent a minimum of 3 days (but not more than 30 days) prior to randomization
  • In acceptable health in the judgment of the study physician, on the basis of interview, medical history, physical exam, ECG, urine test and lab tests
  • Females with childbearing potential must have a negative serum pregnancy test on the screening visit and a negative urine pregnancy test at randomization and agree to use non-hormonal effective birth control for the study duration and one month thereafter

Exclusion Criteria

  • A medical condition or chronic use of a medication that contraindicates the administration of mifepristone
  • Significant medical disorders or clinically significant findings on ECG (e.g., prolongation of the corrected QT interval,urine or blood tests that increase potential risk or interfere with study participation as determined by the Study Physician. Note: serum potassium below the normal range must be replaced to normal prior to randomization; individuals with serum potassium outside the range of normal will not be randomized
  • Liver function tests more than 3 times the upper limit of normal or elevated bilirubin
  • Female subjects with childbearing potential who are pregnant, nursing, or refuse to use effective non hormonal birth control for the 1-week of medication administration and one month thereafter
  • Meets Diagnostic and Statistical Manual -V criteria for a major Axis I disorder including mood or anxiety disorders or substance use disorders other than alcohol or nicotine use disorders
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02179749). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search